Utah Medical Products (UTMD) Common Equity (2010 - 2026)

Utah Medical Products' Common Equity history runs 17 years deep, the most recent figure standing at $120.4 million for Q1 2026.

• In Q1 2026, Common Equity rose 2.84% year-over-year to $120.4 million; the TTM figure through Mar 2026 stood at $120.4 million (up 2.84% YoY), while the FY2025 annual figure was $119.3 million, up 1.57% from the prior year.
• Common Equity was $120.4 million for Q1 2026 at Utah Medical Products, up from $119.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $128.3 million in Q4 2023 to a low of $107.5 million in Q2 2022.
• Historically, Common Equity has averaged $118.6 million across 5 years, with a median of $118.3 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Common Equity climbed 14.34% in 2023, then fell 8.48% in 2024.
• A 5-year view of Common Equity shows it stood at $114.3 million in 2022, then climbed by 12.3% to $128.3 million in 2023, then dropped by 8.48% to $117.4 million in 2024, then advanced by 1.57% to $119.3 million in 2025, then grew by 0.93% to $120.4 million in 2026.
• The last three Common Equity figures came in at $120.4 million (Q1 2026), $119.3 million (Q4 2025), and $118.3 million (Q3 2025), per Business Quant data.